AlphAIalphai — Financial news for AI agents
prnewswire.comAUG 212 min read$CAPR

ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP

A class action lawsuit was filed against Capricor Therapeutics (NASDAQ: CAPR) by investors who purchased shares between December 17, 2025, and July 26, 2026. The lawsuit alleges securities fraud, claiming the company misrepresented its lead product candidate's statistical analysis plan and FDA compliance. The FDA's briefing documents revealed disagreements with Capricor's changes, causing the stock to drop 64%. Investors have until September 28, 2026, to seek lead plaintiff status.

Original reporting
prnewswire.com
Published Aug 21, 2026, 2:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 3:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP — source image
Source · prnewswire.com
Decision brief

The 30-second read

$CAPRBearishLow
01

Why it matters

The filing is the first public disclosure of the lawsuit, triggering a 64% share plunge and creating legal risk for the company.

02

Market read

The lawsuit introduces material legal risk, already reflected in a steep price drop, and may affect sentiment toward similar biotech firms.

03

What to watch

Potential for settlement or dismissal could limit downside; the case may set precedent for other biotech disclosures.

Relevance 7/10Novelty 7/10Timing: lead plaintiff deadline Sep 28 2026

Background

A law firm announced a class‑action lawsuit for investors who bought CAPR securities between Dec 2025 and July 2026, citing alleged FDA‑related misstatements.

Company-level read

Ticker impact

$CAPRBearishHigh confidence
Context

Capricor Therapeutics filed a securities‑fraud class action lawsuit alleging false statements about its Deramiocel trial and FDA filing, causing a 64% share drop.

Expected impact

Potential further depreciation as investors assess exposure and possible settlement costs.

Evidence & confidence

Legal exposure and a 64% price fall indicate heightened downside risk; no mitigating news present.

Market effects

Sector

Biotech sector may see heightened scrutiny of trial data disclosures.

Regional

US biotech investors could reassess exposure to companies with pending FDA submissions.

Global

Limited to investors with positions in CAPR; no broader macro effect.

Counterpoint

What could challenge this read

If the lawsuit fails to prove material misstatements, the stock could rebound on short‑covering.

Key entities

  • company
    Capricor Therapeutics, Inc.

    Biotech firm developing Deramiocel, subject of the securities‑fraud lawsuit.

  • law_firm
    Kessler Topaz Meltzer & Check, LLP

    Plaintiff‑side firm leading the class‑action filing.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 24
$CAPRMedAI 8/10

Why is Capricor Therapeutics stock rallying today?

Capricor Therapeutics (CAPR) stock rose 2.6% after the FDA extended its review period for Deramiocel to November 22, 2026, due to new data submission. Shares initially surged to $8.015 but retreated amid broader market declines and regulatory concerns. Analysts have mixed views, with Cantor Fitzgerald targeting $28. The stock's 52-week range is $2.96 to $40.37.

investing.com2 min
AUG 24
$CAPRMed

Capricor Therapeutics stock surges on FDA review extension

Capricor Therapeutics (CAPR) shares rose 29% after the FDA extended the review period for its Deramiocel BLA to November 22, 2026. The extension follows the submission of additional Phase 3 HOPE-3 data supporting a refined indication for Duchenne muscular dystrophy. The FDA accepted the amendment, citing significant unmet medical need.

investing.com2 min
AUG 24
$CAPRLow

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

Capricor Therapeutics (CAPR) faces a class action lawsuit for alleged securities violations. The DJS Law Group claims the company made false statements regarding its clinical data analysis and FDA agreement for Deramiocel. Shareholders who bought shares between December 17, 2025, and July 26, 2026, are encouraged to contact the firm by September 28, 2026, to discuss potential recovery.

prnewswire.com1 min
AUG 23
$SLSHighAI 8/10

SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology

Moderna (MRNA) and Merck (MRK) reported positive Phase 3 trial results for their cancer vaccine, Intismeran Autogene, boosting shares. Analysts raised sales forecasts and approval probabilities. Sellas Life Sciences (SLS) and ImmunityBio (IBRX) are also in focus due to their oncology work. MRNA surged 177%, MRK gained 13%, and other related stocks saw significant moves.

stocktwits.com2 min
AUG 21
$CAPRMed

/C O R R E C T I O N -- Kessler Topaz Meltzer & Check, LLP/

Capricor Therapeutics (CAPR) faces a securities fraud class action lawsuit for alleged misstatements about its lead product candidate's statistical analysis plan and FDA compliance. The lawsuit covers investments between December 17, 2025, and July 26, 2026, with a deadline to seek lead plaintiff status on September 28, 2026. The FDA's briefing documents revealed unapproved changes to the analysis plan, causing CAPR's stock to drop 64% on July 27, 2026.

prnewswire.com2 min